566155-76-8

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyridinemethanamine, alpha,alpha-dimethylis used as a key intermediate in the synthesis of various pharmaceuticals. Its unique chemical structure allows it to form a wide range of active pharmaceutical ingredients, contributing to the development of new drugs for the treatment of various diseases.
Used in Agrochemical Industry:
In the agrochemical industry, 4-Pyridinemethanamine, alpha,alpha-dimethylis utilized as a precursor in the production of various agrochemicals, such as pesticides and herbicides. Its reactivity and ability to form stable compounds make it a valuable component in the development of effective and environmentally friendly agricultural products.
Used in Chemical Reactions:
4-Pyridinemethanamine, alpha,alpha-dimethylserves as a reagent in various chemical reactions, facilitating the synthesis of a broad spectrum of organic compounds. Its versatility in reacting with different chemical groups makes it an essential component in the production of specialty chemicals.
Used in Dye and Pigment Manufacturing:
4-PYRIDINEMETHANAMINE, ALPHA,ALPHA-DIMETHYLis also used in the manufacturing of dyes and pigments, where its unique properties contribute to the development of vibrant and stable colorants for various applications, including textiles, plastics, and printing inks.
Overall, 4-pyridinemethanamine, alpha,alpha-dimethylis a crucial chemical compound with diverse applications across multiple industries, making it an indispensable component in the development of innovative products and technologies.

Upstream product

• 100-48-1 pyridine-4-carbonitrile 
• 917-54-4 methyllithium 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 1539276-43-1 N-[(1S,2R)-1-benzyl-2-hydroxy-3-(1-methyl-1-pyridin-4-ylethylamino)propyl]-5-piperidin-1-yl-N',N'-dipropylisophthalamide 

Relevant academic research and scientific papers

3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF

The present disclosure provides a compound of Formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, R3, Rx, and n are as defined herein, and methods of making and using same.

NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND

The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt: [wherein, R1 represents optionally substituted C1-4 alkyl, n shows integer of 1 to 4, R2 represents optionally substituted C1-4 alkyl or hydrogen atom, R3 represents optionally substituted C1-4 alkyl, R4a, R4b, R4c, and R4d, similarly or differently, represent optionally substituted C6-14 aryl, optionally substituted C1-4 alkyl, or hydrogen atom and the like, A represents optionally substituted C6-14 aryl or optionally substituted 5 to 11 membered heteroaryl].

Plasmepsin inhibitory activity and structure-guided optimization of a potent hydroxyethylamine-based antimalarial hit

Antimalarial hit 1SR (TCMDC-134674) identified in a GlaxoSmithKline cell based screening campaign was evaluated for inhibitory activity against the digestive vacuole plasmepsins (Plm I, II, and IV). It was found to be a potent Plm IV inhibitor with no selectivity over Cathepsin D. A cocrystal structure of 1SR bound to Plm II was solved, providing structural insight for the design of more potent and selective analogues. Structure-guided optimization led to the identification of structurally simplified analogues 17 and 18 as low nanomolar inhibitors of both, plasmepsin Plm IV activity and P. falciparum growth in erythrocytes.

PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS

Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.

Rapid Ti(Oi-Pr)4 facilitated synthesis of α,α,α-trisubstituted primary amines by the addition of Grignard reagents to nitriles under microwave heating conditions

A series of carbinamines (α,α,α-trisubstituted amines) have been prepared in a simple and efficient one-pot procedure by the addition of Grignard reagents to a series of aliphatic, aromatic and heteroaromatic nitriles. The resulting magnesium imines are subsequently converted to the desired amine after treatment with Ti(Oi-Pr)4 and additional microwave heating. Key to this procedure is the use of microwave heating for both steps of the reaction protocol, which significantly improves both reaction yields and reduces reaction times. In general, the Grignard addition reaction is complete within 5-10 min at 100 °C followed by conversion with Ti(Oi-Pr)4 and additional microwave heating to give the target amines in good yields.

Acridone-based inhibitors of inosine 5′-monophosphate dehydrogenase: Discovery and SAR leading to the identification of N-(2-(6-(4-ethylpiperazin-1- yl)pyridin-3-yl)propan-2-yl)-2-fluoro-9-oxo-9,10-dihydroacridine-3-carboxamide (BMS-566419)

Inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the de novo synthesis of guanosine nucleotides, catalyzes the irreversible nicotinamide-adenine dinucleotide dependent oxidation of inosine-5′- monophosphate to xanthosine-5′-monophosphate. Mycophenolate Mofetil (MMF), a prodrug of mycophenolic acid, has clinical utility for the treatment of transplant rejection based on its inhibition of IMPDH. The overall clinical benefit of MMF is limited by what is generally believed to be compound-based, dose-limiting gastrointestinal (GI) toxicity that is related to its specific pharmacokinetic characteristics. Thus, development of an IMPDH inhibitor with a novel structure and a different pharmacokinetic profile may reduce the likelihood of GI toxicity and allow for increased efficacy. This article will detail the discovery and SAR leading to a novel and potent acridone-based IMPDH inhibitor 4m and its efficacy and GI tolerability when administered orally in a rat adjuvant arthritis model.